Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Xcite, ReNeuron, CPL Resources

Thu, 28th Jan 2010 11:25

Shares in Xcite Energy jumped after the oil group said its subsidiary Xcite Energy Resources has concluded an agreement with BP subsidiary BP Oil International to market and sell Xcite's crude oil from the Bentley field in the North Sea.ReNeuron group climbed after the stem cell developer said Phase 1 trials for its ReN001 stroke treatment should be given the green light soon following a favourable response to data provided to the UK Gene Therapy Advisory Committee.Irish recruitment group CPL Resources tumbled Thursday as it reported a big drop in gross profit and much lower revenue for the six months to 31 December.Gross profit fell 37% to €13m and profit before tax and an impairment charge of €4.5m in 2008 slumped to €2.4m from €6m. Revenue sank to €91.4m from €118.9m.Publishing Technology, which provides software and services to the publishing industry, says delays to project spend in both the UK and US because of the recession mean revenue and earnings before interest, tax, depreciation and amortisation (EBITDA) will be unchanged from the year before.But earnings before tax are expected to be 'significantly' better as 2009 contains no further amortisation of intangible assets or provisions for onerous leases.Product development software specialist Sopheon predicts revenues for the year ended 31 December 2009 will exceed £8m, although that's down from £9.3m in 2008.Chairman Barry Mence says a profitable fourth quarter shows that 'we reacted appropriately to balancing investment with cost containment'. 'Our current pipeline, coupled with our unique solution set and the continued maturing of our chosen market, gives me continued confidence in our quest to improve shareholder value.'Internet booth and WiFi hotspot provider Spectrum Interactive has completed the roll-out of WiFi services across the motorway service station estate of Moto Hospitality. 'This is an important contract for Spectrum, as it is first to bring Spectrum's WiFi service to the UK motorway services sector.Film finance provider and movie promoter Intandem has made a 'positive start' to 2010. It has completed one film, "The Kid", which it expects to show at the Berlin Flim Festival in February, and has four more films in post-production, all of which should be ready for the Cannes film festival.The s still in advanced negotiations to settle the £5.7m loan and expects to make a further announcement in due course.Asia-focused online advertising sales company Pixel Interactive is to lose a customer that provided a substantial proportion of its turnover in 2009. The company is in negotiations with the customer to minimise the impact on Pixel, but the change is likely to have a material impact on Pixel's revenue and profit forecasts for 2010.Online tech retailer Expansys cut losses sharply in the six months to October to just £162,000 against £1.73m. Revenues for the period were £20.4m (2008: £25.3m), but fell 6% on the six months to 30 April 2009. Pre-tax losses were £24,000 (2008: £1.1m). Chief executive Roger Butterworth has stepped down to pursue other business opportunities.Electronic displays group Densitron returned to profitability in the second half of 2009 and expects to return a small profit for the year as a whole.Advanced Medical Solutions says Cardinal Health, a major US healthcare services company, is marketing and distributing AMS's LiquiBand topical skin adhesive range in the US to hospitals, care centres, and surgeries.Hansard Global reports new business in Q2 2009/10 was 25% ahead of Q1 at £40.9m. The group had $1.16bn of Assets under Administration at 31 December 2009, up 15.6% since 30 June 2009. Policyholder cash flows have been strong through the period;
More News
23 Nov 2021 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Nov 2021 12:20

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

Read more
26 Oct 2021 19:06

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

TRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests

Read more
26 Oct 2021 14:02

ReNeuron enters cancer therapy collaboration with UCL

(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.

Read more
21 Oct 2021 16:40

Director dealings: Reneuron Group non-executive makes share purchase

(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.

Read more
21 Oct 2021 14:07

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

DIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:14

ReNeuron treats first Oxford patient as part of expanded study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.

Read more
11 Oct 2021 11:51

ReNeuron upbeat on positive data from Spain collaboration

(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more
11 Oct 2021 11:05

IN BRIEF: ReNeuron gets positive results from exosome drug data

IN BRIEF: ReNeuron gets positive results from exosome drug data

Read more
11 Oct 2021 10:59

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Read more
1 Oct 2021 11:15

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

TRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows

Read more
1 Oct 2021 10:33

ReNeuron gets approval to restart RP clinical study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.

Read more
9 Sep 2021 16:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
6 Aug 2021 10:55

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

ReNeuron taps Oxford Biomedica executive Catherine Isted as CFO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.